Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia | Zendy

Xianqi Feng | Zendy; Xiangyun Chen | Zendy; Shumin Nie | Zendy; Yanyan Chang | Zendy; Fanjun Meng | Zendy; Jingjing Zhou | Zendy; Chunxia Mao | Zendy; Tianlan Li | Zendy; Xueshen Yan | Zendy; Junxia Huang | Zendy; Shanshan Liu | Zendy; Yan Gao | Zendy; Shuxin Xiao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia

Author(s) -

Xianqi Feng,

Xiangyun Chen,

Shumin Nie,

Yanyan Chang,

Fanjun Meng,

Jingjing Zhou,

Chunxia Mao,

Tianlan Li,

Xueshen Yan,

Junxia Huang,

Shanshan Liu,

Yan Gao,

Shuxin Xiao

Publication year - 2017

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.204849

Subject(s) - decitabine , medicine , myelodysplastic syndromes , myeloid leukemia , international prognostic scoring system , anemia , incidence (geometry) , leukemia , oncology , bone marrow , biochemistry , gene expression , chemistry , physics , optics , dna methylation , gene

Decitabine is reported to be valuable in treating multiple malignant blood diseases. However, the application of decitabine in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) has not been fully examined. Thus, our study aimed to investigate the clinical efficacy and safety of decitabine in treating such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research